Search
ubrogepant (Ubrelvy)
Indications:
- treatment of migraine attack (FDA-approved Dec 2019)*
* 22% effective
* when taken during the prodrome phase, ubrogepant decreases likelihood of moderate to severe migraine [4]
Dosage:
- 50 mg & 100 mg PO
Pharmacokinetics:
- gepants able to cross the blood brain barrier
Adverse effects:
- somnolence, nausea, dry mouth [3]
Mechanism of action:
- CGRP receptor antagonist
- gepants do not cause vasoconstriction
General
gepant
Database Correlations
PUBCHEM cid=68748835
References
- George J.
Oral CGRP Inhibitor Helps Relieve Migraine Attack
About 20% report being pain-free within 2 hours.
MedPage Today. April 26, 2018
https://www.medpagetoday.com/meetingcoverage/aan/72559
- Trugman J, et al
Efficacy, safety, and tolerability of ubrogepant for the acute
treatment of migraine: Results from a single attack phase II
Study, ACHIEVE I.
American Academy of Neurology (AAN) 2018.
- FDA News Release. Dec 23, 2019
FDA approves new treatment for adults with migraine.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine
- Windle ML
Rapid Rx Quiz: Headache Medications
Medscape. Sept 12, 2022
https://reference.medscape.com/viewarticle/980181
- Dodick DW, Goadsby PJ, Schwedt TJ et al.
Ubrogepant for the treatment of migraine attacks during the prodrome:
a phase 3, multicentre, randomised, double-blind, placebo-controlled,
crossover trial in the USA.
Lancet. 2023 Nov 15:S0140-6736(23)01683-5.
PMID: 37979595
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01683-5/fulltext
- HIGHLIGHTS OF PRESCRIBING INFORMATION
UBRELVY (ubrogepant) tablets,
https://media.allergan.com/products/Ubrelvy_pi.pdf